Marco Boorsma Ph.D.

Marco Boorsma, Ph.D., is a General Partner at Forbion. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion, he was Business Development Director and Project Manager at DSM Pharmaceutical Products and a Scientist at Cytos Biotechnology in Switzerland. Marco also serves on the board of directors of Escalier Biosciences, NorthSea Therapeutics, Milestone Pharmaceuticals, RSPR Pharma, Prexton Therapeutics, and Engene, and is an observer to the board of directors of Exosome Diagnostics and Oxyrane. Previously, he served on the board of directors of Dezima Pharma, which was sold to Amgen, and on the board of directors of Akarna Therapeutics, which was sold to Allergan. After obtaining a master’s degree in Molecular Biology from the University of Groningen, he received his Ph.D. in Biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.